Chemical inhibitors of CAPS2 operate through a variety of mechanisms to disrupt its function in vesicle exocytosis and neurotransmitter release. BAPTA-AM, a calcium chelator, enters cells in a membrane-permeable form and, once inside, binds to calcium ions, thus inhibiting CAPS2 by depriving it of the calcium necessary for its role in vesicle exocytosis. Similarly, inhibitory chemicals such as ω-Conotoxin GVIA and ω-Agatoxin IVA target specific calcium channels. ω-Conotoxin GVIA blocks N-type calcium channels, preventing calcium influx, while ω-Agatoxin IVA targets P/Q-type calcium channels, both crucial for the calcium-dependent activation of CAPS2 in neurotransmitter release. SNX-482 also plays a role in this context by inhibiting R-type calcium channels, which are involved in the regulation of CAPS2-mediated vesicle trafficking.
Further into the cellular mechanism, ML-9 inhibits myosin light chain kinase, which is essential for actin-myosin interactions. This inhibition disrupts the cytoskeletal dynamics necessary for vesicle movement, a process in which CAPS2 is involved. Thapsigargin contributes to the inhibition by targeting the SERCA pump, leading to the depletion of intracellular calcium stores and therefore reducing the calcium-dependent vesicle release facilitated by CAPS2. The small molecule Exo1 disrupts SNARE-complex formation, which is essential for vesicle fusion to the plasma membrane, a process in which CAPS2 is implicated. Tetanus Toxin and Clostridium Botulinum Neurotoxin A achieve inhibition by targeting components of the SNARE complex; Tetanus Toxin cleaves synaptobrevin, which is critical for the fusion of vesicles at the plasma membrane in neurotransmitter release, a process regulated by CAPS2. Lastly, Dynasore inhibits the GTPase activity of dynamin, blocking vesicle scission, while Endosidin 2 inhibits exocyst complex assembly, and Latrunculin A binds to actin, preventing its polymerization, all of which are essential for the proper functioning of CAPS2 in vesicle trafficking and neurotransmitter release.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator. It inhibits CAPS2 by chelating intracellular calcium that is necessary for CAPS2-mediated vesicle exocytosis. | ||||||
ω-Agatoxin IVA | 145017-83-0 | sc-302015 | 100 µg | $463.00 | ||
ω-Agatoxin IVA is a P/Q-type calcium channel blocker. It inhibits CAPS2 by inhibiting calcium channels that provide the calcium ions required for CAPS2's function in vesicle priming. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
ML-9 is a kinase inhibitor that can inhibit myosin light chain kinase (MLCK). It inhibits CAPS2 by disrupting the actin-myosin interactions which are essential for vesicle movement and secretion involving CAPS2. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor, which leads to depletion of intracellular calcium stores. This inhibits CAPS2 by reducing the calcium-dependent vesicle release that CAPS2 facilitates. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1 is a small molecule that inhibits exocytosis. It inhibits CAPS2 function by disrupting the SNARE-complex formation which is essential for vesicle fusion to the plasma membrane, a process where CAPS2 is involved. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a dynamin inhibitor, which inhibits the GTPase activity of dynamin. It inhibits CAPS2 by blocking vesicle scission from the donor membrane, which is essential for CAPS2's function in vesicle trafficking. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A binds to actin and prevents its polymerization. It inhibits CAPS2 by disrupting the cytoskeletal dynamics necessary for vesicle transport and secretion processes involving CAPS2. | ||||||